Fisher Asset Management LLC increased its position in shares of Core Laboratories Inc. (NYSE:CLB - Free Report) by 19.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 990,267 shares of the oil and gas company's stock after acquiring an additional 161,278 shares during the period. Fisher Asset Management LLC owned about 2.11% of Core Laboratories worth $18,350,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of Core Laboratories by 0.5% in the first quarter. Vanguard Group Inc. now owns 5,392,034 shares of the oil and gas company's stock worth $92,096,000 after acquiring an additional 27,701 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in Core Laboratories by 8.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 27,450 shares of the oil and gas company's stock valued at $469,000 after buying an additional 2,070 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Core Laboratories by 23.9% during the second quarter. GAMMA Investing LLC now owns 4,425 shares of the oil and gas company's stock worth $90,000 after buying an additional 855 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Core Laboratories by 136.8% during the second quarter. SG Americas Securities LLC now owns 24,508 shares of the oil and gas company's stock worth $497,000 after buying an additional 14,158 shares during the last quarter. Finally, Fermata Advisors LLC acquired a new position in shares of Core Laboratories during the second quarter worth $235,000. 97.81% of the stock is owned by institutional investors.
Core Laboratories Trading Down 0.7 %
NYSE:CLB traded down $0.14 during trading hours on Thursday, hitting $20.41. 198,880 shares of the company were exchanged, compared to its average volume of 419,225. The company has a fifty day simple moving average of $19.42 and a 200 day simple moving average of $19.52. Core Laboratories Inc. has a one year low of $13.82 and a one year high of $25.13. The stock has a market capitalization of $958.25 million, a price-to-earnings ratio of 31.40, a price-to-earnings-growth ratio of 1.40 and a beta of 2.35. The company has a current ratio of 2.48, a quick ratio of 1.79 and a debt-to-equity ratio of 0.55.
Core Laboratories (NYSE:CLB - Get Free Report) last released its earnings results on Wednesday, October 23rd. The oil and gas company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.04. Core Laboratories had a net margin of 5.83% and a return on equity of 15.84%. The business had revenue of $134.40 million for the quarter, compared to analyst estimates of $134.16 million. During the same quarter in the previous year, the business earned $0.22 earnings per share. Core Laboratories's revenue for the quarter was up 7.2% on a year-over-year basis. Sell-side analysts expect that Core Laboratories Inc. will post 0.8 EPS for the current fiscal year.
Core Laboratories Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, November 25th. Stockholders of record on Monday, November 4th were given a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a dividend yield of 0.20%. The ex-dividend date was Monday, November 4th. Core Laboratories's dividend payout ratio (DPR) is 6.15%.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the company. Citigroup reduced their price objective on Core Laboratories from $15.00 to $14.00 and set a "sell" rating on the stock in a research report on Thursday, October 31st. StockNews.com upgraded Core Laboratories from a "sell" rating to a "hold" rating in a report on Thursday, November 7th. Two research analysts have rated the stock with a sell rating and three have assigned a hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $17.00.
Get Our Latest Analysis on Core Laboratories
About Core Laboratories
(
Free Report)
Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.
Featured Articles
Before you consider Core Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Core Laboratories wasn't on the list.
While Core Laboratories currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
